• Home
  • Articles
  • Dr. Eliaz Babaev
  • Michael Afremov
  • Senator Rudy Boschwitz
  • Blake Vanderhyde
  • More
    • Home
    • Articles
    • Dr. Eliaz Babaev
    • Michael Afremov
    • Senator Rudy Boschwitz
    • Blake Vanderhyde
  • Home
  • Articles
  • Dr. Eliaz Babaev
  • Michael Afremov
  • Senator Rudy Boschwitz
  • Blake Vanderhyde

Superbug Treatments

Superbug TreatmentsSuperbug TreatmentsSuperbug Treatments

The Future of Medicine?

Superbug Treatments

Superbug TreatmentsSuperbug TreatmentsSuperbug Treatments

The Future of Medicine?

greatest disease threat - Bacteria that resist antibiotiCS

Problem - Drug-Resistant Bacteria Pose a Major Global Health Challenge

Drug-resistant bacteria are recognized as one of the leading global health risks. Click here and here to learn more.    According to various models and reports, including those referenced by the United Nations and the O’Neill Review, antimicrobial resistance (AMR) could lead to approximately 10 million deaths per year by 2050 and cause substantial economic losses on a global scale.

Superbug Threat

Mayo Clinic Observation

In 2007, researchers at the Mayo Clinic were evaluating an FDA-cleared medical device designed for wound cleansing. During their analysis of its effectiveness on chronic wounds, they observed an unexpected effect in laboratory electron microscopy: the device’s low-frequency sound waves appeared to damage several types of antibiotic-resistant bacteria (often called superbugs).


Use of Noncontact Low-Frequency Ultrasound in the Treatment of Chronic Foot and Leg Ulcerations: A 51-Patient Analysis
Steven J. Kavros, DPM; Erik C. Schenck, MPT — Journal of the American Podiatric Medical Association (Vol. 97, No. 2) 

"It is clear there is cell wall destruction of the bacteria after the application of noncontact low frequency ultrasound therapy".   "Further clinical and basic science investigations using this technology are warranted."


Learn more about the Mayo Clinic study


A follow-up study was conducted in 2010 at Winston-Salem State University.


The Effects of Low-Frequency Ultrasound (35 kHz) on Methicillin-Resistant Staphylococcus aureus (MRSA) In Vitro
Teresa Conner-Kerr, PT, PhD, CWS, CLT — Wound Management & Prevention (Vol. 56, Issue 5)


Conclusions:  In vitro, sound waves:


  • Cause direct damage to bacterial cell walls.
  • Alter the genetic code of bacteria, making them less virulent.
  • Decrease antibiotic resistance, making bacteria more susceptible to therapeutic agents.


Learn more about the Winston Salem study.


  

Important Note These findings are from laboratory (electron microscopy and in-vitro) studies only. The device is currently FDA 510(k)-cleared solely for wound cleansing, debridement, and removal of debris as part of standard wound care. It is not cleared or approved for any antimicrobial or infection-treatment indications. Any future clinical application for such uses would require extensive additional research, safety validation, and regulatory review.


Key Takeaway

This Device is FDA 510(k) cleared for Wound Cleaning Only

While these early laboratory observations are intriguing and warrant further independent scientific investigation, they do not constitute evidence of clinical efficacy. Claims of treatment or cure would be premature.

Electron Micrographs

MRSA

Scanning and transmission electron micrographs of methicillin-resistant Staphylococcus aureus during the control and experimental  periods (× 40,000).  Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007 

VRE

Scanning and transmission electron micrographs of vancomycin-resistant enterococci during

the control and experimental periods (× 40,000).  Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007 

P. aeruginosa

Scanning and transmission electron micrographs of Pseudomonas aeruginosa during the

control and experimental periods (× 40,000).  Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007 

S. aureus

Scanning electron micrographs of Staphylococcus aureus during the control and experimental periods (× 40,000).  Journal of the American Podiatric Medical Association • Vol 97 • No 2 • March/April 2007 

The Qoustic Wound Therapy System

The Qoustic Wound Therapy System

An FDA-approved medical device delivers focused sound waves to wound beds. In a feasibility study, researchers observed something that warranted further investigation.  Remarkably, it went largely unnoticed.

Historical Parallel

Some Important Discoveries Go Unnoticed For Years - Hidden in Plain View

In the summer of 1928, a young Scottish physician named Alexander Fleming left a stack of dirty petri dishes in his laboratory sink. They were smeared with dangerous bacteria. When he returned from vacation, he discovered something astonishing: one dish was covered with bacteria, except for a clear area surrounding a patch of mold. He realized that the mold had secreted a substance that killed several strains of the bacteria. Remarkably, this breakthrough went largely unnoticed for 13 years, hidden in plain view.  It was not until 1941 that Fleming’s discovery led to the development of the world’s first antibiotic, penicillin — a breakthrough that changed the course of history.

About Us

Dr. Eliaz Babaev

Co-Founder, CEO, and President.  Learn More.

Michael Afremov

Co-Founder and Investor.  Learn More

Senator Rudy Boschwitz

Senator Rudy Boschwitz

Senator Rudy Boschwitz

Former U.S. Senator and Ambassador.  Advisor to Arobella Medical, LLC.  Learn More.

Blake Vanderhyde, Esq

Senator Rudy Boschwitz

Senator Rudy Boschwitz

Strategist, AI Entrepeneur, Lawyer. Advisor to Arobella Medical, LLC.  Learn More.


Copyright © 2026 Superbug Treatments - The Future of Medicine? - All Rights Reserved.     

FULL DISCLOSURE: This website is provided for informational and educational purposes only. It does not constitute an offer to sell securities, a solicitation of interest in any securities offering, medical advice, or investment advice. Certain statements in this article may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, including but not limited to: failure of in vivo scientific validation, adverse FDA classification or pathway decisions, inability to secure development financing, unforeseen competitive developments, regulatory changes, and loss of key inventor knowledge. The antimicrobial applications discussed here are investigational and are not FDA-cleared for antimicrobial indications. As of the date of publication, no legal entity has been formed or identified for purposes of any securities offering related to this technology. Any future financing, if any, would be conducted only through formal offering materials and in compliance with applicable federal and state securities laws. Do not rely on this content for investment, legal, or medical decisions.

  • Articles

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept